

MessageFrom: Neil Gittoes

Sent: 19 June 2006 17:49

To: Alana Miller

Subject: RE: **\*\*CORRECTION\*\*** Cinacalcet for the treatment of hyperparathyroidism

Dear Alana

In the Expert written personal perspectives section, Dr Hutchison and I are affiliated to the NKF. In fact we were representing the RCP:

§ Dr Neil Gittoes, Consultant Endocrinologist, National Kidney Federation

§ Dr Alastair Hutchison, Consultant Renal Physician, National Kidney Federation

§ Christopher Payne, patient expert, National Kidney Federation

§ Steve Rowe, patient expert, National Kidney Federation

I was disappointed to see that the Committee left no leeway for prescribing cinacalcet in the context of the rare dire clinical need context as was described at the meeting. In other respects I acknowledge the proposals set out by the Committee.

BW

Neil

Dr Neil Gittoes

Senior Lecturer and Consultant Endocrinologist

-----Original Message-----

From: Vicky Marvin

Sent: 15 June 2006 16:07

To: Vicky Marvin

Cc: Alana Miller

Subject: **\*\*CORRECTION\*\*** Cinacalcet for the treatment of hyperparathyroidism

**\*\*CORRECTION\*\***

Please note, the ACD sent to you earlier today contains an error on page 2. The correct closing date for comments is July 13 2006. I have attached an amended version of the ACD to this email – please delete the previous version.

Apologies for any confusion or inconvenience this error has caused.

\*\*\*\*\*  
\*\*\*\*\*

Dear Consultee/Commentator,

Please note, a CD containing the evaluation report was sent via Roya Mail. You should receive this today.

Regards,

Vicky Marvin

-----  
15 June 2006

Dear Consultee/Commentator

Health Technology Appraisal

Cinacalcet hydrochloride for the treatment of secondary hyperparathyroidism in patients with end-stage renal disease on maintenance dialysis therapy

Appraisal Consultation Document

You are invited to comment on the enclosed Appraisal Consultation Document (ACD) and evaluation report for the above appraisal. The Appraisal Committee is interested in receiving your comments on the ACD under the following general headings:

- i) whether you consider that all of the relevant evidence has been taken into account;
- ii) whether you consider that the summaries of clinical and cost effectiveness are reasonable interpretations of the evidence and that the preliminary views on the resource impact and implications for the NHS are appropriate;
- iii) whether you consider that the provisional recommendations of the Appraisal Committee are sound and constitute a suitable basis for the preparation of guidance to the NHS.

If you wish to comment on the evaluation report, please do so under a separate heading to your comments on the ACD.

We prefer to receive comments in electronic format, either by email to [Alana.miller@nice.org.uk](mailto:Alana.miller@nice.org.uk) or on compact or floppy disk. Please use Microsoft Office software products. Comments sent by post should be addressed to Alana Miller, Technology Appraisal Project Manager, at the above address.

Please note that your comments, along with a summary table of these comments and the action taken in response to them will be released to consultees and commentators with the Final Appraisal Determination (FAD) for this appraisal, and published on the Institute's web site.

Please remember it is your responsibility to ensure that if the comments you make on this ACD or Evaluation Report contain commercial in confidence or academic in confidence information they are clearly labeled.

In the light of comments received, the Appraisal Committee will reconsider the ACD at a meeting on 25 July 2006. In order to include your views in the papers for this meeting, your comments must be submitted before 5pm on Thursday 13 July 2006.

The ACD and evaluation report will be posted on the Institute's website 5 working days after circulation to consultees and commentators. People who are not formal consultees or commentators for this appraisal can comment on the ACD through an email link on the website. However, we do not wish to receive comments from formal consultees and commentators via the website. Please send your comments directly to the Technology Appraisal Project Manager, either by email or by post.

I must emphasise that the documents enclosed with this letter, and their contents, are confidential until they are published on the Institute's website. They are released to you only for the purpose of informing the Appraisal Committee's consideration of this technology. Accordingly, neither the documents nor their contents should be divulged to anyone other than those individuals within your organisation who need to see them to enable you to prepare your response. You must ensure that anyone to whom you show the documents is aware of their confidentiality.

The use of any information contained in the ACD to make investment decisions regarding any shares or other securities, or the passing of such information to someone else for such use, may constitute insider dealing, which is a criminal offence under section 52 of the Criminal Justice Act 1993. It may also be an offence to encourage someone else to deal in shares or securities, the price of which would be affected by the disclosure to the public of any information contained in the ACD.

Yours sincerely,